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Background: There are now several lines of evidence to suggest that protein synthesis and translation
factors are involved in the regulation of cell proliferation and cancer development.
Aims: To investigate gene expression patterns of eukaryotic releasing factor 3 (eRF3) in gastric cancer.
Methods: RNA was prepared from 25 gastric tumour biopsies and adjacent non-neoplastic mucosa. Real
time TaqMan reverse transcription polymerase chain reaction (RT-PCR) was performed to measure the
relative gene expression levels. DNA was isolated from tumour and normal tissues and gene dosage was
determined by a quantitative real time PCR using SYBR Green dye.
Results: Different histological types of gastric tumours were analysed and nine of the 25 tumours revealed
eRF3/GSPT1 overexpression; moreover, eight of the 12 intestinal type carcinomas analysed over-
expressed the gene, whereas eRF3/GSPT1 was overexpressed in only one of the 10 diffuse type
carcinomas (Kruskal-Wallis Test; p , 0.05). No correlation was found between ploidy and transcript
expression levels of eRF3/GSPT1. Overexpression of eRF3/GSPT1 was not associated with increased
translation rates because the upregulation of eRF3/GSPT1 did not correlate with increased eRF1 levels.
Conclusions: Overexpression of eRF3/GSPT1 in intestinal type gastric tumours may lead to an increase in
the translation efficiency of specific oncogenic transcripts. Alternatively, eRF3/GSPT1 may be involved in
tumorigenesis as a result of its non-translational roles, namely (dis)regulating the cell cycle, apoptosis, or
transcription.
G
astric cancer is a major cause of cancer related death
worldwide, particularly in developing countries.1 Two
histological types of tumour are recognised according
to Laure´n’s classification: the intestinal and the diffuse types,
which are characterised by different carcinogenic pathways.2–4
Frequent genomic aberrations,5–7 differential expression of
some genes,8–10 genomic instability,11 12 and specific muta-
tions13–15 have been reported in gastric carcinomas, but the
precise molecular events underlying the development of
gastric tumours are still not clear. At present, prognosis
remains poor: most patients have advanced disease at
diagnosis and curative surgery remains the most effective
treatment.16
‘‘Several lines of evidence support a role for eukaryotic
translation factors in cancer development, but the role they
play in the development and progression of cancer is still
unknown’’
The involvement of protein synthesis in the regulation of
cell proliferation and cancer development is currently one
important field in cancer research.17–21 Changes in the
expression pattern of translation factors can lead to several
changes in the tumour cell, such as an increase in the overall
rate of protein synthesis and/or overexpression of specific
proteins involved in cell growth and proliferation.21–24 Several
lines of evidence support a role for eukaryotic translation
factors in cancer development, but the role they play in the
development and progression of cancer is still unknown.
Several translation initiation and elongation factors have
been shown to be overexpressed in different types of
cancers—for example, eukaryotic initiation factor 3S8
(eIF3S8; 16p11.2) in testicular seminomas,25 eIF3-p40
(8q23) in breast and prostate cancers,26 eIF-4E (4q21–q25)
and eIF-2a (14q24.1) in non-Hodgkin lymphomas,27 and
eEF1A2 (20q13.3) in ovarian tumours28—but there have been
no such studies on translation release factors.
Eukaryotic release factor 3 (eRF3) has many functions in
eukaryotic cells. It controls the regulation of the cell cycle at
the G1 to S phase transition,29 and it regulates protein
synthesis as a GTP dependent stimulator of eRF1 in
translation termination.30 It was also reported to have a key
role as an initiator of the mRNA degradation machinery,31 32
in the recycling of ribosomes in successive cycles of
translation,33 and probably also in transcription regulation.34
Two genes encoding eRF3 are presently known, named eRF3/
GSPT1 and eRF3/GSPT2, and mapping in the human genome
to 16p13.1 and Xp11.21–23, respectively.29 35
Because no studies have examined the expression pattern
and the occurrence of genetic alterations of eukaryotic release
factors in human tumours, we decided to investigate the role
of eRF3/GSPT1 in gastric cancer. In our study, we analysed
the expression pattern of the translation termination factors
in gastric tumour samples and corresponding non-neoplastic
adjacent mucosa using a quantitative real time reverse
transcription polymerase chain reaction (RT-PCR). We also
determined eRF3/GSPT1 gene dosage by real time PCR in 35
gastric tumours.
MATERIALS AND METHODS
Patients and tissue samples
We analysed 35 gastric tumours collected from surgical
resections after informed consent was obtained. The tumours
were diagnosed as gastric cancers after histopathological
examination performed in the department of pathology.
Patients were aged 33–87 years (mean, 66.3).
Tissue samples were stored in RNAlater (Ambion, Austin,
Texas, USA) at 220 C˚ immediately after surgery until RNA
Abbreviations: eIF, eukaryotic initiating factor; eRF, eukaryotic release
factor; PCR, polymerase chain reaction; RT, reverse transcription
621
www.jclinpath.com
 group.bmj.com on December 10, 2013 - Published by jcp.bmj.comDownloaded from 
extraction. Freshly frozen samples from 25 gastric tumours
were obtained, together with a sample from the adjacent
non-cancerous tissue, for gene expression analysis. The
samples were classified as 10 diffuse type, 12 intestinal type,
and three other carcinomas (one mixed and two early). Ten
additional formalin fixed, paraffin wax embedded carcinoma
samples and adjacent normal tissues were used for the gene
dosage assay.
DNA extraction, RNA extraction, and cDNA synthesis
RNA was extracted from fresh tissues using the SV Total RNA
Isolation System (Promega, Mannheim, Germany), as
recommended by the manufacturer. First strand cDNA was
synthesised using MultiScribeTM reverse transcriptase
(Applied BioSystems, Foster City, California, USA), with
random hexamers, according to the manufacturer’s instruc-
tions in a total volume of 50 ml; samples were incubated for
10 minutes at 25 C˚, 30 minutes at 48 C˚, and finally for five
minutes at 95 C˚.
DNA was extracted from two 7 mm thick formalin fixed,
paraffin wax embedded tissue sections using chelex resins36
and from fresh tissues using the DNeasy tissue kit (Qiagen,
Hilden, Germany), according to the manufacturer’s protocol.
Real time PCR
Gene expression levels
Expression of the eukaryotic translation factors eRF3/GSPT1,
eRF3/GSPT2, and eRF1 in tumour samples relative to their
normal adjacent tissues was investigated using real time
quantitative RT-PCR based on TaqManH fluorescence meth-
odology. Gene specific primers and TaqMan probes labelled
with 59FAM and 39TAMRA were designed for each gene
(table 1). To avoid the detection of amplification of genomic
DNA the probes were localised in an exon–exon boundary
(except for eRF3/GSPT2, which does not have introns).
Human 18S rRNA (TaqMan predeveloped assay reagents for
gene expression; Applied BioSystems) was used as the
endogenous control gene. Reactions were performed with
TaqMan Universal PCR Master Mix (Applied BioSystems) in
a 25 ml reaction volume. All reactions were performed in
triplicate and included a negative control. PCR reactions were
performed in the GeneAmpH 5700 Sequence Detection
System (Applied BioSystems). Cycling conditions were: two
minutes at 50 C˚, 10 minutes at 95 C˚, and 40 cycles of 15
seconds at 95 C˚ and one minute at 60 C˚.
Relative quantification of the mRNA levels of the target
genes (quantity of transcripts of the target in tumour samples
relative to normal tissues) was determined using the DDCT
method. Briefly, the amount of target was normalised to the
endogenous reference gene (18S rRNA) and its expression in
tumour samples was calculated relative to a calibrator
(normal adjacent sample). Final results are expressed as N-
fold difference in tumour expression relative to non-
cancerous adjacent tissue.
Gene dosage of eRF3/GSPT1
Gene dosage was assessed by quantitative real time PCR
using SYBR Green dye I as the fluorescent signal. This assay
relies on a comparison of the amount of product generated
from the target gene (eRF3/GSPT1) and that generated from
a disomic reference gene (b actin), assuming equal PCR
efficiencies for both. Table 1 shows the primers used for
eRF3/GSPT1 and b actin genomic DNA. A fragment of
genomic DNA from eRF3/GSPT1 was amplified using SYBR
Green PCR Master Mix (Applied BioSystems) in a 20 ml
reaction volume and the endogenous control gene b actin was
measured simultaneously. Each series of PCR reactions
included triplicates for all tumour and normal samples, a
non-template control, and a four point standard curve,
established using serial dilutions (1/2, 1/5, 1/10, and 1/100)
of a known disomic sample for both genes. PCR reactions
were performed in the iCycler iQ Real-Time PCR Detection
System (BioRad, Hercules, California, USA). Cycling condi-
tions were: two minutes at 50 C˚, 10 minutes at 95 C˚, and 40
cycles of 15 seconds at 95 C˚ and one minute at 60 C˚. To
confirm the specificity of the PCR, after the amplification
reaction, the products were submitted to a melting curve
analysis and subsequent gel electrophoresis.
In each experiment the threshold cycle was manually
adjusted and Ct values were averaged for each sample. A
standard curve was established for each gene using the serial
dilutions. For each sample, the amount of eRF3/GSPT1 and
b actin was determined from the standard curve. The gene
dosage of eRF3/GSPT1 was calculated by the ratio of its
amount and the amount of the reference gene. Theoretically,
the ratio of tumour to normal is expected to be 1 for disomic
tumour samples, greater than 1 if there are allele amplifica-
tions, and less than 1 in the presence of allele deletions.
Statistical analysis
The relation of gene expression levels and histological types
of gastric tumours was evaluated by a Kruskal-Wallis H
test performed in SPSS 12.0 for Windows. Differences
were considered significant when the p values were less
than 0.05.
Table 1 Primers and probes used in real time PCR
assays
Oligonucleotide sequence (59–39)
Gene expression
eRF1 F: TGCATCTAACATTAAGTCACGAGT
R: TCCACAGTATACAACCAGACCATT
P: AACCGCCTTTCAGTCCTGGGAGCC
eRF3/GSPT1 F: CGCCAGGTGCTCCTAAGAAAG
R: CAAATACATTATTTGTCCTCCAATGGT
P: ACTTGCCAGCATCTACGTGCCCAATG
eRF3/GSPT2 F: GAGTTCGTGCCGTCCTTCCT
R: CCCGACTCAGCCGCCCACCCT
P: CCGTCCCATCCTTTTACCTTGAG
Gene dosage
eRF3/GSPT1 F: ATAATGATGTACACGGTCACAGTT
R: TTCTTGAAGAGAGATTAGTATGATGAA
b Actin F: AACACTGGCTCGTGTGACAA
R: CAGACCTACTGTGCGCCTACT
Primers and TaqMan probes used in gene expression assays were
designed in Molecular Baecon software (BioRad); primers used in the
gene dosage assay were designed in Primer3 software (http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi).
eRF, eukaryotic release factor; F, forward primer; P, TaqMan probe; PCR,
polymerase chain reaction; R, reverse primer.
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Figure 1 Relative expression of eukaryotic release factor 3/GSPT1 in
25 gastric cancer (GC) tumours (open bars) and normal adjacent
mucosa (black bars) analysed by TaqMan real time reverse transcription
polymerase chain reaction.
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RESULTS
Gene expression levels
Nine of the 25 gastric cancers examined overexpressed eRF3/
GSPT1 in tumour tissue compared with adjacent non-
neoplastic mucosa (fig 1). To evaluate the relation between
the level of eRF3/GSPT1 expression and the different
histopathological types, which differ in their epidemiology,
aetiology, pathogenesis, and behaviour,2–4 tumours were
classified into groups as follows: intestinal type carcinomas
(well differentiated cells, which retain cell cohesion, allowing
the formation of glandular structures with sharp margins),
diffuse type carcinomas (contain small undifferentiated cells
or small cell clusters with deceptive margins, which invade
large areas of the stomach and can lead to early metastasis),
and other types, including mixed and early carcinomas.
Overexpression was seen in eight of the 12 intestinal type
carcinomas analysed, but in only one of the 10 diffuse type
carcinomas (table 2).
Relative overexpression was detected in nine of 25 tumours
when compared with non-neoplastic mucosa. Different levels
of expression were detected: in two tumours, expression was
two to fivefold higher; in four tumours it was five to tenfold
higher; and in three it was more than tenfold higher than in
normal adjacent mucosa. In only four of 25 tumours was
expression less than half that seen in non-neoplastic mucosa
and in none was it more than five times less.
Only one of 10 diffuse type carcinomas overexpressed the
gene, whereas overexpression was seen in eight of 12
intestinal type tumours; none of the other types of tumours
overexpressed or underexpressed eRF3/GSPT1.
To investigate whether there was a correlation between
the eRF3/GSPT1 expression level and translation termina-
tion, and consequently translation rates, we analysed the
expression pattern of the gene encoding eRF1—the most
important factor in the termination step of translation. In
intestinal type tumours, eRF1 was overexpressed in a third of
the samples and underexpressed in another third. In diffuse
type cancers, this gene was underexpressed in half of the
samples and overexpressed in a quarter. There were no
correlations between eRF3/GSPT1 and eRF1 gene expression
levels.
The pattern of eRF3/GSPT2 expression was also investi-
gated, but no expression was detected either in normal
mucosa or in gastric tumour samples.
eRF3/GSPT1 gene dosage assay
Validation of standard curves
Standard curves were constructed for target and control
genes for every assay. The dynamic range was wide. A strong
linear correlation between the Ct and the log of the starting
amount of DNA was determined (r2 . 0.990).
The efficiency (E) of amplification, calculated by the
formula E = 101/m 2 1 (where m is the slope of the
standard curve), was similar for both genes and ranged from
95% to 100% in all assays.
Melting curves and gel electrophoresis showed the
presence of a single band of the expected size.
Gene dosage quantification
Quantitative results from the normal tissues were first
evaluated for gene dosage alterations and ranged from 0.69
to 1.20 (fig 2A), which is in the range of expected values for
disomic samples. Loss of genetic material was seen in three
tumours (fig 2B). We have not found eRF3/GSPT1 amplifica-
tion in the samples studied so far.
Relation between eRF3/GSPT1 levels of expression
and gene dosage
Among the tumours analysed for eRF3/GSPT1 expression we
detected allele deletions in three tumours (two intestinal and
one diffuse type) and none of them was underexpressed.
Thus, there was no association between eRF3/GSPT1 expres-
sion and gene copy number.
DISCUSSION
Using real time RT-PCR, we have shown that eRF3/GSPT1,
which encodes eukaryotic release factor 3, is highly expressed
at the mRNA level in eight of 12 intestinal type gastric
tumours, whereas only one in 10 of the diffuse type tumours
overexpressed this gene. Several factors can lead to changes
in the gene expression patterns seen in tumour cells. One
such factor is DNA copy number alterations, which can lead
to underexpression or overexpression of certain genes and
thus be responsible for cancer development. The detection of
deletions (especially monoallelic deletions) in tumour sam-
ples is particularly difficult because they are present in only a
fraction of the cells in the sample as a result of contamination
with adjacent non-cancerous cells. It is also difficult to
choose an endogenous control gene to use as reference,
because aneuploidy is frequent in tumours. We solved these
difficulties by using real time PCR, which is a very accurate
and sensitive technique, and using the b actin gene as the
disomic endogenous control reference; this gene showed
minimal variation among all the normal and tumour samples
analysed. Furthermore, tumour samples always showed
minimal residual contamination with normal cells and were
as homogeneous as possible.
Because we did not detect amplification of eRF3/GSPT1 in
the tumour samples analysed for gene dosage, changes in
gene copy number cannot be responsible for the over-
expression of the gene seen in intestinal type gastric
carcinomas, so that alterations in the regulation of gene
expression must be involved.
The overexpression of eRF3/GSPT1 was not associated with
increased translation rates because the upregulation of eRF3/
GSPT1 did not correlate with increased amounts of eRF1. We
also investigated the expression of eRF3/GSPT2, but this gene
was not expressed in gastric tissues. In addition, we failed to
detect eRF3/GSPT2 expression in breast and small intestinal
tissues (data not shown). Interestingly, gene expression was
detected in thyroid gland and liver tissue, indicating that the
expression of this factor has a tissue specific pattern.
The molecular pathway by which eRF3/GSPT1 overexpres-
sion contributes to gastric cancer development is unclear,
although there are several possible mechanisms.
Table 2 Frequency of tumours in which eRF3/GSPT1 was underexpressed, overexpressed, or did not vary
Histological classification Underexpressed No variation Overexpressed
Diffuse 3/10 (30%) 6/10 (60%) 1/10 (10%)
Intestinal 1/12 (8.3%) 3/12 (25%) 8/12 (66.7%)
Others 0/3 (0%) 3/3 (100%) 0/3 (0%)
Expression was measured by real time polymerase chain reaction.
Differences in overexpression and underexpression between the histological types were assessed using the Kruskal-Wallis test and p,0.05 was taken as
significant.
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It is now known that signalling pathways do not stimulate
the translation of all mRNAs equally. Changes in the
expression or availability of the components of the transla-
tion machinery can lead to an increase in the overall rate of
protein synthesis or can affect the spectrum of mRNAs
translated,21 24 37–39 activating the translation of specific
mRNA molecules involved in growth and proliferation,
leading to the overexpression of their products.17 Therefore,
it is possible that the overexpression of eRF3/GSPT1 could
increase the translation efficiency of specific oncogenic
transcripts.
Although there are differences in the proliferation rate
between intestinal and diffuse type gastric tumours, incon-
sistent and sometimes conflicting results have been reported.
Nevertheless, lower proliferating rates have been assigned to
intestinal tumours using different labelling indexes.40 41
Therefore, it seems unlikely that the higher amounts of
eRF3/GSPT1 mRNA seen in intestinal type tumours are
necessary for their rapid proliferating activity. Moreover,
about a third of the samples underexpressed eRF1, the key
gene for translation termination, which can result in reduced
translation efficiency. However, in diffuse type tumours, half
of the samples underexpressed eRF1, and eRF3 levels were
not altered.
‘‘The effects of eRF3/GSPT1 on chromosome segregation
and cytokinesis could be a possible mechanism by which
this gene influences tumorigenesis’’
Other non-translational roles of eRF3 have recently been
studied. This gene was shown to affect the tubulin
cytoskeleton,42 suggesting a role in the control of chromo-
some segregation. More recently, its involvement in the
assembly of the actin cytoskeleton in yeast was also
demonstrated.43 Deregulation of eRF3 expression also
resulted in abnormal meiotic chromosome segregation and
defects in cytoskeleton assembly in spermatids of Drosophila
melanogaster.44 Taking all these results into consideration, the
effects of eRF3/GSPT1 on chromosome segregation and
cytokinesis could be a possible mechanism by which this
gene influences tumorigenesis.
A proteolytically processed isoform of the eRF3/GSPT1
protein, which functions as an IAP binding protein (inhibitor
of apoptosis), has recently been described.45 This newly
identified role of eRF3/GSPT1, which can potentiate or inhibit
apoptosis, could be another possible mechanism by which
this gene influences cancer development. Different patterns
of expression of several apoptosis related proteins have been
found in intestinal and diffuse types of gastric tumour.
Diffuse type tumour cells may avoid cellular death as a result
of the expression of survivin, an apoptosis inhibiting
protein,46 and Bcl-xl, an antiapoptotic protein, in addition
to the absence of Fas, a member of the tumour necrosis factor
receptor family.47 The increased expression of eRF3/GSPT1 in
intestinal type tumours might have an effect on the apoptosis
pathway.
Our study provides compelling evidence for the involve-
ment of translation factors in tumorigenesis. Moreover, this
is the first time that a release factor has been associated with
the development or progression of cancer.
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